SIRPA and lymphoma: Correspondingly, SIRPα blocking agents also increased neutrophil-mediated anticancer effects, with antibody KWAR23 promoting the neutrophil-mediated phagocytic removal of lymphoma cells by rituximab and breast cancer cells by trastuzumab [166].